Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants.
Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D. Gahrton G, et al. Among authors: niederwieser d. Bone Marrow Transplant. 2005 Mar;35(6):609-17. doi: 10.1038/sj.bmt.1704861. Bone Marrow Transplant. 2005. PMID: 15696179
An allogeneic anti-cancer effect after hematopoietic stem cell transplantation.
Barkholt L, Hentschke P, Zetterquist H, Mattsson J, Uzunel M, Wersäll P, Martola J, Albin N, Aschan J, Wijkström H, Tillegård A, Oman S, Wernerson A, Niederwieser D, Thörne A, Ringdén O. Barkholt L, et al. Among authors: niederwieser d. Transplant Proc. 2001 Feb-Mar;33(1-2):1862-4. doi: 10.1016/s0041-1345(00)02726-3. Transplant Proc. 2001. PMID: 11267544 No abstract available.
HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.
Clark RE, Hermans J, Madrigal A, Nachbaur D, Kropshofer G, Gratwohl A, Apperley J, Niederwieser D; Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation. Clark RE, et al. Among authors: niederwieser d. Br J Haematol. 2001 Jul;114(1):36-41. doi: 10.1046/j.1365-2141.2001.02897.x. Br J Haematol. 2001. PMID: 11472342 Free article.
Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation.
de Witte T, Pikkemaat F, Hermans J, van Biezen A, Mackinnan S, Cornelissen J, Gratwohl A, Delforge M, Iriondo A, Kuentz M, Harousseau J, Fauser A, Wandt H, Runde V, Niederwieser D, Apperley J; EBMT, CLWP-MDS subcommittee. de Witte T, et al. Among authors: niederwieser d. Leukemia. 2001 Dec;15(12):1878-84. doi: 10.1038/sj.leu.2402296. Leukemia. 2001. PMID: 11753608
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H, Gluckman E, Friedrich W, Cordonnier C, Socie G, Tyndall A, Niethammer D, Ljungman P, Gratwohl A, Apperley J, Niederwieser D, Bacigalupo A; European Group for Blood and Marrow Transplantation. Urbano-Ispizua A, et al. Among authors: niederwieser d. Bone Marrow Transplant. 2002 Apr;29(8):639-46. doi: 10.1038/sj.bmt.1703535. Bone Marrow Transplant. 2002. PMID: 12180107
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Among authors: niederwieser d. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review.
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T; Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). Olavarria E, et al. Among authors: niederwieser d. Leukemia. 2003 Sep;17(9):1707-12. doi: 10.1038/sj.leu.2403068. Leukemia. 2003. PMID: 12970768 Clinical Trial.
629 results